4.62 USD
+0.15 (+3.36%)
4.85 USD
+0.23 (+4.98%)
ATRA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. While ATRA is still in line with the averages on profitability rating, there are concerns on its financial health. ATRA is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year ATRA was profitable.
- ATRA had a negative operating cash flow in the past year.
- ATRA had negative earnings in each of the past 5 years.
- In the past 5 years ATRA always reported negative operating cash flow.
1.2 Ratios
- ATRA has a better Return On Assets (77.57%) than 99.62% of its industry peers.
- ATRA's Return On Invested Capital of 271.93% is amongst the best of the industry. ATRA outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.57% | ||
| ROE | N/A | ||
| ROIC | 271.93% |
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 15.40%, ATRA belongs to the top of the industry, outperforming 92.05% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 27.44%, ATRA belongs to the top of the industry, outperforming 96.02% of the companies in the same industry.
- ATRA has a better Gross Margin (81.63%) than 85.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.44% | ||
| PM (TTM) | 15.4% | ||
| GM | 81.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ATRA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, ATRA has more shares outstanding
- Compared to 5 years ago, ATRA has less shares outstanding
- ATRA has a worse debt/assets ratio than last year.
2.2 Solvency
- ATRA has an Altman-Z score of -83.77. This is a bad value and indicates that ATRA is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -83.77, ATRA is not doing good in the industry: 93.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -83.77 |
ROIC/WACC41.58
WACC6.54%
2.3 Liquidity
- A Current Ratio of 1.02 indicates that ATRA should not have too much problems paying its short term obligations.
- ATRA has a worse Current ratio (1.02) than 86.36% of its industry peers.
- A Quick Ratio of 1.02 indicates that ATRA should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.02, ATRA is doing worse than 85.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 108.46%, which is quite impressive.
- Looking at the last year, ATRA shows a very strong growth in Revenue. The Revenue has grown by 51.27%.
- ATRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 85.07% yearly.
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
3.2 Future
- The Earnings Per Share is expected to grow by 18.24% on average over the next years. This is quite good.
- ATRA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.91% yearly.
EPS Next Y116.48%
EPS Next 2Y41.63%
EPS Next 3Y20.11%
EPS Next 5Y18.24%
Revenue Next Year5.25%
Revenue Next 2Y-29.08%
Revenue Next 3Y-39.56%
Revenue Next 5Y5.91%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 2.12, the valuation of ATRA can be described as very cheap.
- ATRA's Price/Earnings ratio is rather cheap when compared to the industry. ATRA is cheaper than 99.62% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.54. ATRA is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 60.39, ATRA can be considered very expensive at the moment.
- 89.77% of the companies in the same industry are more expensive than ATRA, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.31, ATRA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.12 | ||
| Fwd PE | 60.39 |
4.2 Price Multiples
- 99.43% of the companies in the same industry are more expensive than ATRA, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.16 |
4.3 Compensation for Growth
- ATRA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ATRA's earnings are expected to grow with 20.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y20.11%
5. Dividend
5.1 Amount
- ATRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
4.62
+0.15 (+3.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-05 2026-03-05/amc
Inst Owners45.78%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change-0.13%
Market Cap33.31M
Revenue(TTM)151.93M
Net Income(TTM)23.40M
Analysts80
Price Target20.06 (334.2%)
Short Float %2.91%
Short Ratio2.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.01%
Min EPS beat(2)63.52%
Max EPS beat(2)140.49%
EPS beat(4)4
Avg EPS beat(4)136.18%
Min EPS beat(4)63.52%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)49.96%
EPS beat(12)7
Avg EPS beat(12)23.63%
EPS beat(16)9
Avg EPS beat(16)20.25%
Revenue beat(2)2
Avg Revenue beat(2)138.29%
Min Revenue beat(2)134.43%
Max Revenue beat(2)142.15%
Revenue beat(4)4
Avg Revenue beat(4)485.59%
Min Revenue beat(4)67.7%
Max Revenue beat(4)1598.08%
Revenue beat(8)6
Avg Revenue beat(8)233.67%
Revenue beat(12)6
Avg Revenue beat(12)128.56%
Revenue beat(16)8
Avg Revenue beat(16)133.26%
PT rev (1m)15.69%
PT rev (3m)19.19%
EPS NQ rev (1m)19.63%
EPS NQ rev (3m)40.72%
EPS NY rev (1m)0%
EPS NY rev (3m)34.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)40.97%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)1.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.12 | ||
| Fwd PE | 60.39 | ||
| P/S | 0.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.16 |
EPS(TTM)2.18
EY47.19%
EPS(NY)0.08
Fwd EY1.66%
FCF(TTM)-9.68
FCFYN/A
OCF(TTM)-9.67
OCFYN/A
SpS21.07
BVpS-5.08
TBVpS-5.08
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.57% | ||
| ROE | N/A | ||
| ROCE | 344.22% | ||
| ROIC | 271.93% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 27.44% | ||
| PM (TTM) | 15.4% | ||
| GM | 81.63% | ||
| FCFM | N/A |
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover5.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.71 | ||
| Cap/Depr | 2.84% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | 116.11 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -83.77 |
F-Score4
WACC6.54%
ROIC/WACC41.58
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
EPS Next Y116.48%
EPS Next 2Y41.63%
EPS Next 3Y20.11%
EPS Next 5Y18.24%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
Revenue Next Year5.25%
Revenue Next 2Y-29.08%
Revenue Next 3Y-39.56%
Revenue Next 5Y5.91%
EBIT growth 1Y134.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.44%
EBIT Next 3Y17.04%
EBIT Next 5Y-3.99%
FCF growth 1Y65.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.05%
OCF growth 3YN/A
OCF growth 5YN/A
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
Can you provide the ChartMill fundamental rating for ATARA BIOTHERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to ATRA.
What is the valuation status of ATARA BIOTHERAPEUTICS INC (ATRA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ATARA BIOTHERAPEUTICS INC (ATRA). This can be considered as Fairly Valued.
How profitable is ATARA BIOTHERAPEUTICS INC (ATRA) stock?
ATARA BIOTHERAPEUTICS INC (ATRA) has a profitability rating of 4 / 10.
What is the financial health of ATARA BIOTHERAPEUTICS INC (ATRA) stock?
The financial health rating of ATARA BIOTHERAPEUTICS INC (ATRA) is 2 / 10.
Can you provide the expected EPS growth for ATRA stock?
The Earnings per Share (EPS) of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 116.48% in the next year.